or Try an Advanced Search...

    Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 9.19 -3.36% -0.32
    ORIC closed down 3.36 percent on Friday, April 19, 2024, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 6
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Flat Down Down
    Historical ORIC trend table...
    Date Alert Name Type % Chg
    Expansion Breakdown Bearish Swing Setup 0.00%
    200 DMA Support Bullish 0.00%
    Hammer Candlestick Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Multiple of Ten Bearish Other -3.36%
    Wide Bands Range Expansion -3.36%
    Gapped Up Strength -3.36%
    Oversold Stochastic Weakness -3.36%
    Slingshot Bearish Bearish Swing Setup -5.84%
    Older End-of-Day Signals for ORIC ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR about 20 hours ago
    60 Minute Opening Range Breakdown about 22 hours ago
    200 DMA Resistance about 23 hours ago
    Fell Below 200 DMA about 23 hours ago
    Down 5% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ORIC Chart by TradingView
    Basic chart:

    Profile

    ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73

    Is ORIC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 15 ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
    Apr 8 ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    Apr 4 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
    Mar 29 ORIC Pharmaceuticals: Rally Seems Overdone
    Mar 26 How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
    Mar 13 ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
    Mar 13 ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
    Mar 11 ORIC Pharmaceuticals files for automatic mixed securities shelf
    Mar 11 ORIC Pharmaceuticals GAAP EPS of -$0.49
    Mar 11 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
    See more ORIC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.63
    52 Week Low 4.89
    Average Volume 617,225
    200-Day Moving Average 9.19
    50-Day Moving Average 12.44
    20-Day Moving Average 11.27
    10-Day Moving Average 9.87
    Average True Range 0.73
    RSI (14) 25.37
    ADX 32.91
    +DI 12.42
    -DI 34.38
    Chandelier Exit (Long, 3 ATRs) 13.16
    Chandelier Exit (Short, 3 ATRs) 10.91
    Upper Bollinger Bands 14.53
    Lower Bollinger Band 8.01
    Percent B (%b) 0.18
    BandWidth 57.91
    MACD Line -1.05
    MACD Signal Line -0.85
    MACD Histogram -0.204
    Fundamentals Value
    Market Cap 616.21 Million
    Num Shares 67.1 Million
    EPS -1.98
    Price-to-Earnings (P/E) Ratio -4.64
    Price-to-Sales 0.00
    Price-to-Book 3.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.21
    Resistance 3 (R3) 10.17 9.78 10.04
    Resistance 2 (R2) 9.78 9.52 9.81 9.98
    Resistance 1 (R1) 9.49 9.36 9.30 9.53 9.93
    Pivot Point 9.10 9.10 9.01 9.13 9.10
    Support 1 (S1) 8.81 8.84 8.62 8.85 8.45
    Support 2 (S2) 8.42 8.68 8.45 8.40
    Support 3 (S3) 8.13 8.42 8.34
    Support 4 (S4) 8.17